Promoting Diversity for Translational Success
In preclinical efficacy studies, several factors are often overlooked, and it is important to evaluate variables like sex, age, species, comorbidities, and genetic background. Incorporating these considerations early on improves the translatability of findings to clinical settings and ultimately improves drug effectiveness. In translational studies, simplifying the complexities related to variables such as sex and age is not viable. These factors must be considered when designing efficacy studies, both in vitro and in vivo. By addressing these factors during the planning stages of preclinical studies, researchers can save time and resources when transitioning to clinical studies. MD Biosciences is invested in studying the effects of diversity in preclinical studies.